CTOs on the Move


 
EdiGENE Corporation is an emerging biotech company focusing on developing transformative therapeutics for unmet medical needs using its proprietary technologies on CRISPR and protein engineering platforms. The company has a strong foundation on intellectual property licensed from the University of Tokyo.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

EdiGENE raised $15M on 04/10/2019

Similar Companies

Tute Genomics

Tute Genomics is a web-based, powerful solution for analyzing genetic sequencing data in a matter of minutes. Tute is robust, secure, professional-grade; a true web application that lives in the cloud and has the ability to analyze and annotate entire human genomes in a rapid and cost-effective way.    What makes Tute stand out above the rest? Tute is built on ANNOVAR, the gold-standard in whole genome interpretation with already over 400 scientific citations. Tute pulls in 125+ annotation types, databases, and scores; more than any other analyses software.    Tute can use your genome variant data in a variety of common formats (VCF, CG masterVar, and more) and uses proprietary machine-learning algorithms to rank each variant. For each genetic variant, Tute presents a human-readable annotation with links to external supporting evidence. Tute supports disease gene finding, biomarker discovery, pharmacogenetics and more.

Nucleome Therapeutics

Decoding the dark matter of the human genome to uncover novel ways to treat disease Discover More

CE and IC Inc

CE and IC Inc is a Burlington, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

NextCure

NextCure is a fully integrated biotechnology company discovering and developing first-in-class immunotherapy-based biologics for cancer and other diseases. The company is focused on understanding biological pathways and leveraging our FIND-IOTM technology to discover, validate and build a proprietary pipeline. We believe identifying and targeting immune pathways will promote identification of effective targets for mediating sustained immunity leading to improved outcomes for cancer patients.

Provident Research

We specialize in recruiting clinical research talent and understand the hiring objectives of our Medical Device, Biotechnology, and Pharmaceutical clients.